SCHEMBL4185056

SCHEMBL4185056

NC(CC(=O)O)Oc1ccc(Cl)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.55
PPARA Q07869 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
FFAR1 O14842 2/20 0.52
RECQL P46063 1/20 0.52
TSHR P16473 1/20 0.50
CHRM1 P11229 1/20 0.47
HTT P42858 1/20 0.45
HPGD P15428 3/20 0.45
MRGPRX4 Q96LA9 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
RAB9A P51151 1/20 0.44
GLA P06280 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
ALOX12 P18054 1/20 0.44
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4182560 0.85 TSHR (0.60) TDP1SMN1; SMN2FFAR1TSHRHTT
SCHEMBL11591588 0.84 TDP1 (0.58) TDP1PPARASMN1; SMN2FFAR1RECQL
SCHEMBL4181107 0.82 LMNA (0.40) TDP1PPARASMN1; SMN2FFAR1RECQL
SCHEMBL757221 0.81 FFAR1 (0.59) TDP1PPARASMN1; SMN2FFAR1RECQL
SCHEMBL4173523 0.77 PPARG (0.50) PPARATSHRCYP1A2CYP2C9CYP2C19
SCHEMBL2463704 0.76 PPARA (0.50) TDP1PPARASMN1; SMN2FFAR1RECQL
Rac-Dichlorprop SCHEMBL28260029 0.75 TSHR (0.68) PPARASMN1; SMN2TSHRHTTHPGD
SCHEMBL4185051 0.75 PPARA (0.68) TDP1PPARASMN1; SMN2RECQLTSHR
SCHEMBL28096041 0.75 PPARA (0.59) TDP1PPARASMN1; SMN2RECQLTSHR
SCHEMBL11593869 0.75 PPARA (0.59) TDP1PPARASMN1; SMN2RECQLTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227680-A1 Amino Acid Derivatives PFIZER, INC. (US) 2009-09-10 US claimed
EP-1951655-A2 AMINO ACID DERIVATIVES Pfizer Limited (GB) 2008-08-06 EP claimed
WO-2007057767-A2 AMINO ACID DERIVATIVES PFIZER LIMITED (GB) 2007-05-24 WO claimed
US-20090227680-A1 Amino Acid Derivatives PFIZER, INC. (US) 2009-09-10 US disclosed
EP-1951655-A2 AMINO ACID DERIVATIVES Pfizer Limited (GB) 2008-08-06 EP disclosed
WO-2007057767-A2 AMINO ACID DERIVATIVES PFIZER LIMITED (GB) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227680-A1 Amino Acid Derivatives OPRL1, OPRK1, AVPR1A TDP1 4257/4885PPARA 1589/4885SMN1; SMN2 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.